Key result
The addition of ribavirin to interferon therapy significantly improves long-term virological response in patients with chronic hepatitis C compared to interferon alone.
Why the study?
Does the addition of ribavirin to interferon therapy improve sustained virological response in patients with chronic hepatitis C?
Does the addition of ribavirin to interferon therapy improve sustained virological response in patients with chronic hepatitis C?
Combination therapy with ribavirin and interferon improves virological response in chronic hepatitis C but is associated with increased adverse effects like hemolytic anemia.
Answers are grounded in this paper and cite their sources.
May improve response in hepatitis C; leaves open benefit-risk balance and relevance versus modern antivirals.
Interferon alfa therapy emerged as an early treatment option for patients with chronic hepatitis C. This therapy, however, fails to produce a sustained virological response in most patients. Various host and viral baseline characteristics, some of which include hepatitis C virus genotype, viral load, presence of cirrhosis, and patient age, affect the response to interferon therapy. The addition of ribavirin to interferon therapy significantly improves long-term virological response in treatment-naive patients and is also more effective than repeat interferon therapy is in patients who fail to initially achieve sustained virological or biochemical responses. However, ribavirin can induce reversible hemolytic anemia, and combination therapy with a ribavirin/interferon regimen is not tolerated as well as interferon is alone. Pegylated interferons used alone or in combination with ribavirin provide improved treatment options for different patient groups with chronic hepatitis C.
No takes yet. Share an insight, caveat, or question.
Thierry Poynard (2004) conducted a review in Chronic hepatitis C. Interferon alfa and ribavirin combination therapy vs. Interferon alfa alone was evaluated. The addition of ribavirin to interferon therapy significantly improves long-term virological response in patients with chronic hepatitis C compared to interferon alone.
Synapse has enriched 10 related papers. Consider them for comparative context: